Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758840 | 0.94 | CNR1 (0.47) | TP53LMNACNR2CNR1MAPT | |
| SCHEMBL5758734 | 0.92 | PDE10A (0.46) | CNR2CNR1KMT2APDE10AELANE | |
| SCHEMBL5759985 | 0.92 | CNR2 (0.49) | CNR2CNR1KMT2APDE10AELANE | |
| SCHEMBL28755625 | 0.90 | CNR2 (0.44) | TP53LMNACNR2CNR1MAPT | |
| SCHEMBL5759095 | 0.90 | TP53 (0.51) | TP53LMNACNR2CNR1MAPT | |
| SCHEMBL5757653 | 0.90 | CNR2 (0.47) | LMNACNR2CNR1MAPTKMT2A | |
| SCHEMBL5758070 | 0.90 | CNR1 (0.53) | LMNACNR2CNR1KMT2APDE10A | |
| SCHEMBL5759118 | 0.89 | ELANE (0.55) | CNR2CNR1KMT2APDE10AELANE | |
| SCHEMBL5757652 | 0.89 | PDE10A (0.48) | CNR2CNR1KMT2APDE10AELANE | |
| SCHEMBL5759073 | 0.89 | TP53 (0.49) | TP53LMNAMAPTKMT2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | TP53 3353/4885LMNA 509/4885CNR2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.